Remibrutinib Efficacy in RemIND Through Week 52
RemIND is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial evaluating remibrutinib 25 mg twice daily in adults with CIndU inadequately controlled by second-generation H1 antihistamines.¹ The trial enrolled 362 patients across 3 cohorts: SD, cold urticaria (ColdU), and cholinergic urticaria (CholU).¹ Patients randomized to placebo switched to remibrutinib at week 24, and the primary endpoint was the proportion of complete responders at week 12 on subtype-specific provocation tests.¹
Frequently Asked Questions
What is remibrutinib approved for in urticaria?
In the US, remibrutinib is approved for adults with CSU or SD whose symptoms are inadequately controlled by H1 antihistamines. SD is the first CIndU subtype with an FDA-approved treatment.
How does remibrutinib work?
Remibrutinib is an oral, highly selective BTK inhibitor. It blocks the BTK pathway involved in histamine release from mast cells.
What did the 52-week RemIND data show?
Among patients initially randomized to remibrutinib, week 52 complete or partial response rates were 46.8% in SD, 83.3% in ColdU, and 58.2% in CholU. Patients who switched from placebo at week 24 reached similar rates.
In the SD cohort, 29.3% of patients receiving remibrutinib achieved a complete response on the Total Fric Score at week 12 vs 14.0% with placebo (P =.0229).³ Responses emerged early. At week 1, complete or partial response rates were 41.8% with remibrutinib vs 19.2% with placebo in SD and 67.4% vs 28.9% in ColdU; at week 2, rates were 65.2% vs 45.6% in CholU.¹
At week 52, complete or partial response rates among patients initially randomized to remibrutinib were 46.8% in SD, 83.3% in ColdU, and 58.2% in CholU.¹ Patients switching from placebo at week 24 reached 47.7%, 88.9%, and 69.8%, respectively.¹ Mosnaim attributed the catch-up in the switch group to the fast onset of action with remibrutinib.
“We're still learning more about the different types of CIndU,” Mosnaim said. “We’re very excited that there was such a robust response in cold urticaria, but we're still trying to better understand mechanisms of action and why the response might be more robust for cold urticaria and [why] cholinergic urticaria had a high placebo response.”
References
Mosnaim GS. Remibrutinib showed sustained efficacy and favorable safety profile through week 52 in chronic inducible urticaria. Presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.